

**Supplemental Digital Content 5.** Snapshot and TRDF analyses of the percentage of participants in the pooled ITT-E population with HIV-1 RNA <50 copies/mL or without TRDF at Week 144 by baseline viral load and CD4+ cell count. DTG, dolutegravir; FTC, emtricitabine; ITT-E, intention-to-treat–exposed; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; TRDF, treatment-related discontinuation equals failure. <sup>a</sup>Percentages estimated from the TRDF Kaplan-Meier analysis.

